The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase

AUTOR(ES)

Lowther, W. Todd

FONTE

The National Academy of Sciences

RESUMO

Methionine aminopeptidase (MetAP) exists in two forms (type I and type II), both of which remove the N-terminal methionine from proteins. It previously has been shown that the type II enzyme is the molecular target of fumagillin and ovalicin, two epoxide-containing natural products that inhibit angiogenesis and suppress tumor growth. By using mass spectrometry, N-terminal sequence analysis, and electronic absorption spectroscopy we show that fumagillin and ovalicin covalently modify a conserved histidine residue in the active site of the MetAP from Escherichia coli, a type I enzyme. Because all of the key active site residues are conserved, it is likely that a similar modification occurs in the type II enzymes. This modification, by occluding the active site, may prevent the action of MetAP on proteins or peptides involved in angiogenesis. In addition, the results suggest that these compounds may be effective pharmacological agents against pathogenic and resistant forms of E. coli and other microorganisms.

Documentos Relacionados

• The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2
• Anti-angiogenic activity of iridoids from Galium tunetanum
• Anti-angiogenic effects of ethanolic extract of Artemisia sieberi compared to its active substance, artemisinin
• Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine
• Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane